Hansen Medical to Present at Barclays Select Series 2013: Select Growth Conference
12 11월 2013 - 6:01AM
Marketwired
Hansen Medical to Present at Barclays Select Series 2013: Select
Growth Conference
MOUNTAIN VIEW, CA--(Marketwired - Nov 11, 2013) - Hansen
Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular
robotics, today announced that President and CEO, Bruce Barclay, is
scheduled to present at the Barclays Select Series 2013: Select
Growth Conference. The conference is being held November 18 - 20,
2013 in New York, NY. Hansen Medical is scheduled to present on
Monday, November 18, 2013 at 9:05 a.m. Eastern Time.
Hansen Medical will provide a live webcast of the audio
presentation. Interested parties may access the live webcast by
visiting the investor relations section of Hansen Medical's web
site at www.hansenmedical.com. A replay of the webcast will be
available at the site after the presentation.
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is a
global leader in intravascular robotics, developing products and
technology designed to enable the accurate positioning,
manipulation and control of catheters and catheter-based
technologies. The Company's Magellan™ Robotic System, 9Fr Magellan™
Robotic Catheter and related accessories, which are intended to
facilitate navigation to anatomical targets in the peripheral
vasculature and subsequently provide a conduit for manual placement
of therapeutic devices, have undergone both CE marking and 510(k)
clearance and are commercially available in the European Union, and
the U.S. In the European Union, the Company's Sensei® X Robotic
Catheter System and Artisan® and Artisan Extend® Control Catheters
are cleared for use during electrophysiology (EP) procedures, such
as guiding catheters in the treatment of atrial fibrillation (AF),
and the Lynx® Robotic Ablation Catheter is cleared for the
treatment of AF. This robotic catheter system is compatible with
fluoroscopy, ultrasound, 3D surface map and patient
electrocardiogram data. In the U.S., the Company's Sensei X Robotic
Catheter System and Artisan and Artisan Extend Control Catheters
are cleared by the U.S. Food and Drug Administration for
manipulation and control of certain mapping catheters in EP
procedures. In the U.S., the Sensei X Robotic Catheter System is
not approved for use in guiding ablation procedures; this use
remains experimental. The U.S. product labeling therefore provides
that the safety and effectiveness of the Sensei X Robotic Catheter
System and Artisan and Artisan Extend Control Catheter for use with
cardiac ablation catheters in the treatment of cardiac arrhythmias,
including AF, have not been established. Additional information can
be found at www.hansenmedical.com.
Forward-Looking Statements
Hansen Medical's presentation will contain forward-looking
statements regarding, among other things, statements relating to
goals, plans, objectives, milestones and future events. All
statements, other than statements of historical fact, are
statements that could be deemed forward-looking statements,
including statements containing the words "plan," "expects,"
"potential," "believes," "goal," "estimate," "anticipates," and
similar words. These statements are subject to risks,
uncertainties, changes in circumstances and other factors that may
cause actual results to differ materially from the information
expressed or implied by forward-looking statements. Important
factors that could cause actual results to differ materially from
those indicated by forward-looking statements are described in the
"Risk Factors" section of the Company's Quarterly Report on Form
10-Q for the quarter ended September 30, 2013 filed with the SEC on
November 8, 2013 and the risks discussed in our other reports filed
with the SEC. Given these uncertainties, you should not place undue
reliance on the Company's forward-looking statements. Hansen
Medical undertakes no obligation to revise or update its
forward-looking statements to reflect events or circumstances in
the future, even if new information becomes available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan
and NorthStar are trademarks of Hansen Medical, Inc. in the United
States and other countries.
Investor Contacts: Peter J. Mariani Chief Financial Officer
Hansen Medical, Inc. 650.404.5800 FTI Consulting, Inc. Brian
Ritchie 212.850.5683 Email Contact John Capodanno 212.850.5705
Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024